How FDA Priority Review Works as Tinlarebant Gets a February Goal Date

The FDA has accepted Belite Bio's new drug application for tinlarebant, an oral drug for Stargardt disease type 1, and granted it Priority Review, the company announced, as reported by Eyewire+ on Aug. 11. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of Feb. 12, 2027.

The application rests on the Phase 3 DRAGON trial. According to the company, tinlarebant produced a statistically significant 35.7% reduction in the growth rate of atrophic retinal lesions compared with placebo. Glance by Eyes On Eyecare reported that the application was submitted on a rolling basis under a Breakthrough Therapy designation, and that the drug also holds Fast Track designation.

Two terms in the announcement, "Priority Review" and "PDUFA date," describe the FDA's review calendar. Neither is a verdict on the drug.

Two review clocks

FDA's Priority Review page traces the system to 1992, when, under the user-fee law, the agency agreed to specific review-time goals and "created a two-tiered system of review times – Standard Review and Priority Review." In the agency's words, "A Priority Review designation means FDA’s goal is to take action on an application within 6 months (compared to 10 months under standard review)."

The designation is meant for drugs that, if approved, would be significant improvements in the safety or effectiveness of treating, diagnosing or preventing serious conditions compared with standard applications. FDA lists examples such as evidence of increased effectiveness, or the elimination or substantial reduction of a treatment-limiting drug reaction.

FDA decides the review designation for every application, though a company may ask for priority review. The agency says it informs the applicant of a Priority Review designation within 60 days of receiving the original application or efficacy supplement.

What the designation does not change

The FDA page is explicit on two limits. Priority Review "does not affect the length of the clinical trial period," and it "does not alter the scientific/medical standard for approval or the quality of evidence necessary." A faster clock means the agency aims to finish its review sooner, not that the application faces a lower bar.

Priority Review is also separate from the other programs named in Belite Bio's announcement. FDA's overview of its expedited programs describes four distinct approaches: Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review. The agency notes that because each implies speed, "there can be confusion about the specific meaning of each and the distinctions among them." FDA describes Fast Track as a process to facilitate development and expedite review, and Breakthrough Therapy as a process to expedite development and review; Priority Review sets the goal for the review itself.

Where the PDUFA date comes from

The "PDUFA date" is the target action date under the agency's user-fee goals. FDA's PDUFA page says Congress created the law in 1992 to let FDA collect user fees from companies that submit certain drug applications, and that the fees "have played an important role in expediting the drug review and approval process." The law must be reauthorized every five years; the current version, PDUFA VII, runs through September 2027.

A target action date is the agency's goal for acting on the application; it does not say what the action will be. For tinlarebant, that date is Feb. 12, 2027.